Skip to content

Clinical study on Fuling Decoction combined with Xiaochaihu Decoction in the treatment of residual dizziness after reduction of benign paroxysmal positional vertigo

Clinical study on Fuling Decoction combined with Xiaochaihu Decoction in the treatment of residual dizziness after reduction of benign paroxysmal positional vertigo

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049073
Enrollment
Unknown
Registered
2021-07-20
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign paroxysmal positional vertigo

Interventions

Sponsors

The Affiliated Hospital to Changchun University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years old; 2. Meet the diagnostic criteria for benign paroxysmal positional vertigo and the diagnostic criteria for vertigo in traditional Chinese medicine; 3. Comply with the successful labeling of benign paroxysmal positional vertigo manual reduction, that is, meet the standard of cure or improvement; 4. Residual dizziness symptoms after manual reduction of benign paroxysmal positional vertigo; 5. No history of severe cerebral and cardiovascular diseases, no history of mental illness and cognitive impairment, no history of serious organic diseases and surgery; those who signed informed consent and were able to adhere to follow-up.

Exclusion criteria

Exclusion criteria: 1. Those who cannot cooperate with diagnosis and treatment, such as mental disorders, cognitive disorders, emotional instability and intolerance; 2. Cerebrovascular disease and acute cardiovascular disease, traumatic brain injury, intracranial space-occupying lesions; 3. Acute lesions of non-BPPV in otolaryngology such as the acute phase of Meniere's disease and the acute phase of sudden deafness; 4. No residual dizziness symptoms after treatment; 5. Those who take vestibular inhibitors, anti-anxiety drugs, and heavy drinkers.

Design outcomes

Primary

MeasureTime frame
Vertigo Disability Rating Scale;Hamilton Anxiety Scale;TCM Syndrome Evaluation Scale;

Countries

China

Contacts

Public ContactWang Yue

The Affiliated Hospital to Changchun University of Chinese Medicine

2573999012@qq.com+86 15844009550

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026